A naukri.com initiative
Bioengineer
5d
110
Image Credit: Bioengineer
PROTACs Outperform MDM2 Inhibition in ER+ Cells
- A study in BMC Cancer highlights the effectiveness of targeting mdm2 with PROTACs in ER+ breast cancer cells, surpassing traditional inhibition methods.
- Mdm2 negatively regulates p53, a tumor suppressor, and its overexpression in cancers leads to unchecked proliferation.
- Direct inhibition of mdm2 faces challenges, prompting the need for more precise approaches in treating cancers, especially in resistant cases.
- The study explores PROTACs as a strategy to degrade mdm2, leveraging the ubiquitin-proteasome system for targeted protein destruction.
- In vitro experiments show PROTACs outperform mdm2 inhibition, halting cell proliferation in ER+ breast cancer cell lines, including resistant and p53-mutated cells.
- PROTAC-induced mdm2 degradation alters key signaling pathways, impacting cell cycle progression and tumor growth in various breast cancer models.
- Notable effects include modulation of p73, Rb activity, and E2F1, showcasing the broad influence of PROTACs on cancer cell biology.
- Additionally, PROTAC treatment downregulates immune-related markers, potentially affecting anti-tumor immunity and suggesting combinational therapy avenues.
- PROTACs signify a paradigm shift in oncology by eliminating oncogenic drivers, offering a promising approach for combating treatment-resistant breast cancers.
- The study's findings support the development of personalized oncology therapies using PROTAC technology to target pivotal proteins involved in cancer progression.
Read Full Article
6 Likes
For uninterrupted reading, download the app